肠道微生物衍生代谢物与NAFLD中肝脂肪变性和纤维化的共享基因效应之间的联系
该研究对156名双胞胎及家庭成员的前瞻性发现队列进行横断面分析,采用非靶向代谢组学检测血清代谢物,并用MRI-PDFF和MRE评估肝脂肪变性和纤维化,以AE模型估计代谢物与两者的共享基因效应。在156名经活检证实NAFLD的独立验证队列中验证,发现3-(4-羟基苯基)乳酸与肝纤维化在发现和验证队列中均保持显著关联。
要点
- 在发现队列中,56种代谢物(含6种微生物代谢物)与肝脂肪变性和纤维化均存在显著共享基因效应。
- 3-(4-羟基苯基)乳酸与肝脂肪变性共享基因效应RG=0.57(95%CI 0.27-0.80,P<0.001),与纤维化RG=0.54(95%CI 0.036-1,P=0.036)。
- 在验证队列中,3-(4-羟基苯基)乳酸与晚期纤维化相关(倍数变化1.26,P=0.037)。
核心结论
- 该概念验证研究提供证据表明,肠道微生物与3-(4-羟基苯基)乳酸之间存在联系,后者与肝脂肪变性和纤维化共享基因效应。
研究设计与样本
- 前瞻性发现队列的横断面分析,纳入156名特征明确的双胞胎及家庭成员,进行非靶向代谢组学分析。
- 肝脂肪变性采用磁共振成像质子密度脂肪分数(MRI-PDFF)评估,纤维化采用磁共振弹性成像(MRE)评估。
- 采用双生子加性遗传与独特环境效应(AE)模型估计代谢物与肝脂肪变性和纤维化的共享基因效应。
- 在156名经活检证实NAFLD的独立前瞻性验证队列中验证发现,其中部分亚组进行鸟枪法宏基因组测序。
主要发现
- 在发现队列中,调整年龄、性别和种族后,56种代谢物(包括6种微生物代谢物)与肝脂肪变性和纤维化均存在显著共享基因效应。
- 在验证队列中,6种代谢物与晚期纤维化相关。
- 在发现和验证队列中,仅3-(4-羟基苯基)乳酸保持与肝纤维化一致且统计学显著关联:较高MRE vs 较低MRE的倍数变化为1.78(P<0.001),晚期纤维化 vs 无晚期纤维化的倍数变化为1.26(P=0.037)。
- 3-(4-羟基苯基)乳酸与肝脂肪变性的共享遗传决定度为RG=0.57(95%CI 0.27-0.80,P<0.001),与纤维化为RG=0.54(95%CI 0.036-1,P=0.036)。
- 在验证队列中,3-(4-羟基苯基)乳酸与仅属于厚壁菌门、拟杆菌门和变形菌门的几种肠道微生物物种丰度显著相关,这些物种先前被报道与晚期纤维化相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Previous studies have shown that gut-microbiome is associated with nonalcoholic fatty liver disease (NAFLD). We aimed to examine if serum metabolites, especially those derived from the gut-microbiome, have a shared gene-effect with hepatic steatosis and fibrosis. This is a cross-sectional analysis of a prospective discovery cohort including 156 well-characterized twins and families with untargeted metabolome profiling assessment. Hepatic steatosis was assessed using magnetic-resonance-imaging proton-density-fat-fraction (MRI-PDFF) and fibrosis using MR-elastography (MRE). A twin additive genetics and unique environment effects (AE) model was used to estimate the shared gene-effect between metabolites and hepatic steatosis and fibrosis. The findings were validated in an independent prospective validation cohort of 156 participants with biopsy-proven NAFLD including shotgun metagenomics sequencing assessment in a subgroup of the cohort. In the discovery cohort, 56 metabolites including 6 microbial metabolites had a significant shared gene-effect with both hepatic steatosis and fibrosis after adjustment for age, sex and ethnicity. In the validation cohort, 6 metabolites were associated with advanced fibrosis. Among them, only one microbial metabolite, 3-(4-hydroxyphenyl)lactate, remained consistent and statistically significantly associated with liver fibrosis in the discovery and validation cohort (fold-change of higher-MRE versus lower-MRE: 1.78, P < 0.001 and of advanced versus no advanced fibrosis: 1.26, P = 0.037, respectively). The share genetic determination of 3-(4-hydroxyphenyl)lactate with hepatic steatosis was RG :0.57,95%CI:0.27-0.80, P < 0.001 and with fibrosis was RG :0.54,95%CI:0.036-1, P = 0.036. Pathway reconstruction linked 3-(4-hydroxyphenyl)lactate to several human gut-microbiome species. In the validation cohort, 3-(4-hydroxyphenyl)lactate was significantly correlated with the abundance of several gut-microbiome species, belonging only to Firmicutes, Bacteroidetes and Proteobacteria phyla, previously reported as associated with advanced fibrosis. Conclusion: This proof of concept study provides evidence of a link between the gut-microbiome and 3-(4-hydroxyphenyl)lactate that shares gene-effect with hepatic steatosis and fibrosis. (Hepatology 2018).
引用
- Caussy C, Hsu C, Lo MT, et al. Link between gut-microbiome derived metabolite and shared gene-effects with hepatic steatosis and fibrosis in NAFLD. Hepatology. 2018. PMID: 29572891. doi:10.1002/hep.29892
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。